{
    "nct_id": "NCT05716516",
    "official_title": "Phase II Study of Estradiol Therapy to Target ER-Mutant and ER-Wild-Type ER+ Metastatic or Advanced Breast Cancer",
    "inclusion_criteria": "* Post-menopausal women with ER+ breast cancer.\n* Metastatic or locoregional recurrence not amenable to treatment with curative\n* intent.\n* Received ≥1 prior line of endocrine-based therapy (e.g., including tamoxifen, aromatase inhibitors, fulvestrant, or combinations) in the advanced/metastatic setting\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* During the study Treatment Phase with 17b-estradiol, no concurrent anti-cancer therapies are allowed with the following exceptions:\n\n  * Exception: Trastuzumab is allowed for the treatment of subjects with a history of HER2+ disease, and will be used at the physician's discretion.\n  * Exception: Anti-resorptive bone therapies (e.g., bisphosphonates, denosumab) are permitted.\n* Any investigational cancer therapy in the last 3 weeks.\n* Known CNS disease, unless clinically stable for ≥ 3 months.\n* History of any of the following:\n\n  * Deep venous thrombosis.\n  * Pulmonary embolism.\n  * Stroke.\n  * Acute myocardial infarction.\n  * Congestive heart failure.\n  * Previous malignancy not treated with curative intent, or with an estimated recurrence risk ≥30%.",
    "miscellaneous_criteria": ""
}